While our study demonstrates the promising potential of IL12/CSF1R‐MM‐IRC18‐LPS nanovesicles for NIR‐II fluorescence imaging‐guided membrane‐targeted mild photothermal‐immunotherapy of glioblastoma, several limitations should be acknowledged. This evidence concerns the gene CSF1R and glioblastoma.